ATAI Launches Phase 3 After FDA Nod on Depression Drug

ATAI Life Sciences has received FDA approval to initiate Phase 3 clinical trials for BPL-003, a nasal spray targeting treatment-resistant depression. This green light followed a successful End-of-Phase 2 meeting that confirmed the study design and efficacy and safety goals. Additionally, its candidate EMP-01 showed positive Phase 2a results for social anxiety, strengthening the company's clinical development profile. Despite a recent 15.6% decline over one week, the stock remains up 137% over the past year. These key developments are expected to support ATAI’s valuation and market momentum.